Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
or

Allogene Therapeutics Inc (ALLO)

Allogene Therapeutics Inc (ALLO)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
2.17 -0.09 (-3.98%) 02/21/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 2.17 unch (unch) 19:45 ET
Quote Overview for Fri, Feb 21st, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
2.14
Day High
2.39
Open 2.35
Previous Close 2.26 2.26
Volume 4,884,700 4,884,700
Avg Vol 9,841,435 9,841,435
Stochastic %K 41.53% 41.53%
Weighted Alpha -55.47 -55.47
5-Day Change +0.76 (+53.90%) +0.76 (+53.90%)
52-Week Range 1.32 - 5.78 1.32 - 5.78
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 454,988
  • Shares Outstanding, K 209,672
  • Annual Sales, $ 100 K
  • Annual Income, $ -327,270 K
  • EBIT $ -276 M
  • EBITDA $ -268 M
  • 60-Month Beta 0.83
  • Price/Sales 9,298.51
  • Price/Cash Flow N/A
  • Price/Book 1.02

Options Overview Details

View History
  • Implied Volatility 202.32% ( +3.95%)
  • Historical Volatility 164.90%
  • IV Percentile 95%
  • IV Rank 28.86%
  • IV High 678.39% on 05/17/24
  • IV Low 9.15% on 08/15/24
  • Put/Call Vol Ratio 0.11
  • Today's Volume 1,463
  • Volume Avg (30-Day) 1,070
  • Put/Call OI Ratio 0.39
  • Today's Open Interest 14,503
  • Open Int (30-Day) 6,528

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.34
  • Number of Estimates 11
  • High Estimate -0.25
  • Low Estimate -0.51
  • Prior Year -0.43
  • Growth Rate Est. (year over year) +20.93%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.32 +64.39%
on 02/12/25
Period Open: 1.84
3.78 -42.59%
on 02/19/25
+0.33 (+17.93%)
since 01/21/25
3-Month
1.32 +64.39%
on 02/12/25
Period Open: 2.11
3.78 -42.59%
on 02/19/25
+0.06 (+2.84%)
since 11/21/24
52-Week
1.32 +64.39%
on 02/12/25
Period Open: 4.44
5.78 -62.42%
on 03/08/24
-2.27 (-51.13%)
since 02/21/24

Most Recent Stories

More News
Optimism in War on Cancer on the Rise, as Biotech Companies Roll Out More Wins

Vancouver, BC – February 18, 2025 – USA News Group News Commentary – Despite optimism coming from the launch of Project Stargate (a $500 billion investment in AI data centers), there is still cause...

ONCY : 0.7256 (-1.79%)
ALLO : 2.17 (-3.77%)
VRCA : 0.7361 (-0.78%)
ONC.TO : 1.03 (-1.90%)
OSTX : 1.7000 (-10.05%)
IBRX : 3.42 (-6.04%)
Optimism in War on Cancer on the Rise, as Biotech Companies Roll Out More Wins

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – Despite optimism coming from the launch of Project Stargate (a $500 billion investment in AI data centers),...

ALLO : 2.17 (-3.77%)
ONCY : 0.7256 (-1.79%)
VRCA : 0.7361 (-0.78%)
ONC.TO : 1.03 (-1.90%)
IBRX : 3.42 (-6.04%)
OSTX : 1.7000 (-10.05%)
Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology

ALLO : 2.17 (-3.77%)
Allogene Therapeutics Announces Participation in February Investor Conferences

ALLO : 2.17 (-3.77%)
Allogene Therapeutics Announces Benjamin M. Beneski as Senior Vice President and Chief Technical Officer

ALLO : 2.17 (-3.77%)
Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases

ALLO : 2.17 (-3.77%)
This Penny Stock Has 270% Upside Potential in 2025. Is It a Buy Now?

Shares of this biotech company have had a rough ride in 2024, but analysts are feeling good about its future.

ALLO : 2.17 (-3.77%)
NVDA : 134.43 (-4.05%)
IOVA : 5.78 (+3.03%)
AZN : 74.22 (-0.46%)
AMZN : 216.58 (-2.83%)
CLLS : 1.5300 (-0.65%)
3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2025

The biotech sector witnessed a see-saw performance in 2024. Though the year started on a positive note, those gains were erased in the second half due to disappointing third-quarter results, guidance cuts,...

ALLO : 2.17 (-3.77%)
IMCR : 29.92 (+0.17%)
DAWN : 12.43 (+1.64%)
Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment

/CNW/ -- USA News Group News Commentary – Immunotherapy is transforming oncology by harnessing the immune system's power to fight cancer like never before....

ALLO : 2.17 (-3.77%)
ONCY : 0.7256 (-1.79%)
CNTX : 0.8140 (+3.04%)
RXRX : 9.28 (-10.34%)
ONC.TO : 1.03 (-1.90%)
ERAS : 1.4100 (-3.42%)
3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying

The year 2024 has been a mixed ride for the biotech industry. It started on a positive note, attracting investors’ attention in areas with great commercial potential, like obesity, immunology and gene...

ALLO : 2.17 (-3.77%)
RZLT : 4.53 (-2.16%)
VNDA : 4.43 (-1.34%)
LOBLAW COMPANIES LIMITED TO ISSUE $400 MILLION OF SENIOR UNSECURED NOTES

/CNW/ - (TSX: L) – Loblaw Companies Limited ("Loblaw" or the "Company") announced today that it has agreed to issue, on a private placement basis to qualified...

RY : 118.88 (-0.65%)
L.TO : 175.89 (+0.65%)
RY.TO : 169.22 (-0.11%)
LOBLAW COMPANIES LIMITED ANNOUNCES INTENTION TO REDEEM SECOND PREFERRED SHARES, SERIES B

/CNW/ - (TSX: L) (TSX: L.PR.B) – Loblaw Companies Limited ("Loblaw" or the "Company") announced today its intention to redeem for cash all of its 9,000,000...

L.TO : 175.89 (+0.65%)
L-PR-B.TO : 24.90 (-0.44%)
From niche grocer to supermarket giant: How T&T plans to repeat success in the U.S.

Canada’s biggest Asian grocery chain is expanding into the U.S., hoping to bring its patented array of food, skin care and more to a new market.

L.TO : 175.89 (+0.65%)
George Weston: Q3 Earnings Snapshot

George Weston: Q3 Earnings Snapshot

WN.TO : 217.50 (-0.83%)
L.TO : 175.89 (+0.65%)
Loblaw Companies reports Q3 profit up from year ago, revenue also higher

BRAMPTON, Ont. — Loblaw Companies Ltd. reported its third-quarter profit rose compared with a year ago, boosted by the reversal of a charge at its President's Choice Bank after a Federal Court of Appeal...

L.TO : 175.89 (+0.65%)
Loblaw Reports Adjusted Diluted Net Earnings Per Common Share(2) growth of 10.6% in the Third Quarter

/CNW/ - Loblaw Companies Limited (TSX: L) ("Loblaw" or the "Company") announced today its unaudited financial results for the third quarter ended October 5,...

L.TO : 175.89 (+0.65%)
Building Permits, Vehicle Sales Due Next Week

Monday U.S. Featured Earnings Monday.Com Ltd (NASDAQ: MNDY) (Q3) EPS of four cents, compared ...

BABA : 143.75 (+5.72%)
HAFN : 5.05 (unch)
AMAT : 171.98 (-2.29%)
CSCO : 63.98 (-1.07%)
NVA.TO : 12.58 (-2.86%)
NU : 10.82 (-18.89%)
BN : 58.86 (-1.95%)
COCH : 1.4800 (-2.89%)
DIS : 108.66 (-1.71%)
SHOP : 115.56 (-6.41%)
ARMK : 35.93 (-2.52%)
ZETA : 20.73 (-7.62%)
Loblaw says it would join with grocery industry in ending property controls

Canada’s biggest grocer says it wants to eliminate commercial property controls in the grocery industry.

L.TO : 175.89 (+0.65%)
Stocks in play: Loblaw Companies Limited

Will release its third-quarter 2024 results on November 13, at approximately 6:30 a.m. (ET). The release ...

L.TO : 175.89 (+0.65%)
Loblaw Companies Limited Announces the Timing of the Third Quarter 2024 Earnings Release

/CNW/ - Loblaw Companies Limited (TSX: L) announced today that it will release its third quarter 2024 results on November 13, 2024, at approximately 6:30 a.m....

L.TO : 175.89 (+0.65%)
LOBLAW COMPANIES LIMITED TO ISSUE $400 MILLION OF SENIOR UNSECURED NOTES

/CNW/ - (TSX: L) – Loblaw Companies Limited ("Loblaw" or the "Company") announced today that it has agreed to issue, on a private placement basis to qualified...

RY : 118.88 (-0.65%)
L.TO : 175.89 (+0.65%)
RY.TO : 169.22 (-0.11%)
LOBLAW COMPANIES LIMITED ANNOUNCES INTENTION TO REDEEM SECOND PREFERRED SHARES, SERIES B

/CNW/ - (TSX: L) (TSX: L.PR.B) – Loblaw Companies Limited ("Loblaw" or the "Company") announced today its intention to redeem for cash all of its 9,000,000...

L.TO : 175.89 (+0.65%)
L-PR-B.TO : 24.90 (-0.44%)
From niche grocer to supermarket giant: How T&T plans to repeat success in the U.S.

Canada’s biggest Asian grocery chain is expanding into the U.S., hoping to bring its patented array of food, skin care and more to a new market.

L.TO : 175.89 (+0.65%)
George Weston: Q3 Earnings Snapshot

George Weston: Q3 Earnings Snapshot

WN.TO : 217.50 (-0.83%)
L.TO : 175.89 (+0.65%)
Loblaw Companies reports Q3 profit up from year ago, revenue also higher

BRAMPTON, Ont. — Loblaw Companies Ltd. reported its third-quarter profit rose compared with a year ago, boosted by the reversal of a charge at its President's Choice Bank after a Federal Court of Appeal...

L.TO : 175.89 (+0.65%)
Loblaw Reports Adjusted Diluted Net Earnings Per Common Share(2) growth of 10.6% in the Third Quarter

/CNW/ - Loblaw Companies Limited (TSX: L) ("Loblaw" or the "Company") announced today its unaudited financial results for the third quarter ended October 5,...

L.TO : 175.89 (+0.65%)
Building Permits, Vehicle Sales Due Next Week

Monday U.S. Featured Earnings Monday.Com Ltd (NASDAQ: MNDY) (Q3) EPS of four cents, compared ...

BABA : 143.75 (+5.72%)
HAFN : 5.05 (unch)
AMAT : 171.98 (-2.29%)
CSCO : 63.98 (-1.07%)
NVA.TO : 12.58 (-2.86%)
NU : 10.82 (-18.89%)
BN : 58.86 (-1.95%)
COCH : 1.4800 (-2.89%)
DIS : 108.66 (-1.71%)
SHOP : 115.56 (-6.41%)
ARMK : 35.93 (-2.52%)
ZETA : 20.73 (-7.62%)
Loblaw says it would join with grocery industry in ending property controls

Canada’s biggest grocer says it wants to eliminate commercial property controls in the grocery industry.

L.TO : 175.89 (+0.65%)
Stocks in play: Loblaw Companies Limited

Will release its third-quarter 2024 results on November 13, at approximately 6:30 a.m. (ET). The release ...

L.TO : 175.89 (+0.65%)
Loblaw Companies Limited Announces the Timing of the Third Quarter 2024 Earnings Release

/CNW/ - Loblaw Companies Limited (TSX: L) announced today that it will release its third quarter 2024 results on November 13, 2024, at approximately 6:30 a.m....

L.TO : 175.89 (+0.65%)

Business Summary

Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company, primarily focused on the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer.'

See More

Key Turning Points

3rd Resistance Point 2.58
2nd Resistance Point 2.48
1st Resistance Point 2.33
Last Price 2.17
1st Support Level 2.08
2nd Support Level 1.98
3rd Support Level 1.83

See More

52-Week High 5.78
Fibonacci 61.8% 4.07
Fibonacci 50% 3.55
Fibonacci 38.2% 3.02
Last Price 2.17
52-Week Low 1.32

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Mastering Fibonacci: The Hidden Order in Market Movements